Olaf Roetzschke obtained his PhD in 1993 at the University of Tübingen, Germany, where he studied biochemistry. He started his career at the Max-Planck Institute of Biology in the group of Hans-Georg Rammensee, where he isolated the first natural T cell antigen and defined the binding motifs of MHC molecules. In 1993 he joined the group of Jack Strominger at Harvard University, carrying out studies on the immune-modulation and antigen-presentation. In 2000 he moved to the Max-Delbrück-Center in Berlin focusing on regulatory T cells (Treg) and MHC ligand-exchange. He joined SIgN as Principal Investigator in July 2008 and since 2011 is also Adjunct Prof. at the Nanyang Technological University (NTU), Singapore and Adjunct Assoc. Prof. at the National University of Singapore (NUS). In 2023 he launched the ‘T-cell Monitoring and Vaccine development’ (T-MoVac) project, a nation-wide platform for the development of personalized cancer vaccines.